Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
TLSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.50 - $10.24
Previous CloseN/A
Volume4.84K
Average Volume (3M)62.84K
Market Cap
$173.60M
Enterprise Value$153.14M
Total Cash (Recent Filing)$1.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 14, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding31,279,264
10 Day Avg. Volume49,544
30 Day Avg. Volume62,844
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.40
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.63
Enterprise Value/Ebitda-2.92
Forecast
1Y Price Target
$11.60Price Target Upside110.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
TriSalus Life Sciences News
PremiumCompany Announcements
TriSalus Life Sciences Reports Strong Growth Amid Challenges
PremiumCompany Announcements
TriSalus Life Sciences Delays Annual Report Filing
PremiumCompany Announcements
TriSalus Life Sciences Reports Strong 2024 Growth---
Bulls Say, Bears Say
Bulls Say
Product PerformanceSales of TriNav increased by 44%, indicating strong market performance.
Reimbursement OpportunitiesThe new CMS HCPCS code effective April 1, 2025, is positioned as upside as this unlocks pre-procedural mapping reimbursement in ~25% of TriNav’s patient volumes.
Revenue GrowthManagement reiterated its expectation that FY25 revenue will grow by over 50% year-over-year, signaling strong growth potential.
Bears Say
Financial ReportingThe company plans to delay filing its 10-K for 2024 due to errors in determining stock-based compensation and R&D expense timing.
Share Conversion ImpactThe upcoming reset for the company’s 4,015,002 shares of Convertible Preferred Stock could potentially double the shares upon conversion.
Stock DilutionThe upcoming reset for the company’s Convertible Preferred Stock could potentially double the shares, which might dilute current stock value.
---
Ownership Overview
44.81% Insiders
2.34% Mutual Funds
4.10% Other Institutional Investors
47.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.50 and its highest was $10.24 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $173.60M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is May 14, 2025 which is in 31 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Mar 27, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.317 by -$0.083.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.22.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 31,279,264 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.317. Following the earnings report the stock price went down -1.434%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
---
TriSalus Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.60 (110.53% Upside)
$11.60 (110.53% Upside)
Blogger Sentiment
Neutral
TLSI Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $422.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.37%
12-Months-Change
Fundamentals
Return on Equity
271.41%
Trailing 12-Months
Asset Growth
-6.82%
Trailing 12-Months
Company Description
TriSalus Life Sciences
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
---
TLSI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
TriSalus Life Sciences demonstrated strong revenue growth and expansion of its PEDD technology despite a challenging economic environment. The issuance of a new HCPCS code by CMS and strategic cost reductions were positive developments. However, the delay in filing the 10-K and ongoing operating losses highlight some operational challenges. The overall sentiment is cautiously optimistic with a focus on future growth.Read More>---
TLSI Stock 12 Month Forecast
Average Price Target
$11.60
▲(110.53% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Vertex Pharmaceuticals
―
Karyopharm Therapeutics
―
Moderna
―
Best Analysts Covering TLSI
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
-1.60%
reiterated a buy rating 18 days ago
Copying William Plovanic's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -1.60% per trade.
---